Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Rating Reaffirmed by Oppenheimer

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report)'s stock had its "outperform" rating reissued by stock analysts at Oppenheimer in a report issued on Monday, Benzinga reports. They presently have a $1.50 price objective on the stock, up from their prior price objective of $1.20.

Separately, B. Riley started coverage on shares of Perspective Therapeutics in a research report on Friday, January 26th. They set a "buy" rating and a $1.20 price objective for the company.

Perspective Therapeutics Stock Performance

Shares of CATX traded up 0.09 during trading hours on Monday, hitting 1.28. The stock had a trading volume of 4,482,900 shares, compared to its average volume of 2,993,032. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.67 and a quick ratio of 2.55. Perspective Therapeutics has a fifty-two week low of 0.21 and a fifty-two week high of 1.36. The stock has a market cap of $359.13 million, a P/E ratio of -12.80 and a beta of 1.56.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of Perspective Therapeutics stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company's stock, valued at 110,934,724.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of Perspective Therapeutics stock in a transaction that occurred on Wednesday, March 6th. The shares were purchased at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at 110,934,724.30. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Markus Puhlmann bought 280,000 shares of Perspective Therapeutics stock in a transaction that occurred on Wednesday, January 24th. The stock was purchased at an average cost of 0.50 per share, for a total transaction of 140,000.00. Following the acquisition, the insider now owns 1,375,425 shares of the company's stock, valued at 687,712.50. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 60,758,439 shares of company stock valued at $57,576,503. 5.72% of the stock is currently owned by corporate insiders.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Perkins Capital Management Inc. purchased a new position in shares of Perspective Therapeutics during the third quarter worth approximately $731,000. HighTower Advisors LLC purchased a new position in shares of Perspective Therapeutics during the third quarter worth approximately $314,000. Taylor & Morgan Wealth Management LLC grew its position in shares of Perspective Therapeutics by 8.7% during the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company's stock worth $251,000 after acquiring an additional 50,000 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Perspective Therapeutics during the third quarter worth approximately $42,000. Finally, Wealth Effects LLC purchased a new position in shares of Perspective Therapeutics during the third quarter worth approximately $30,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.